These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35928523)

  • 1. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
    Brinkman HJM; Zuurveld M; Meijers JCM
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation.
    Lu G; Lin J; Bui K; Curnutte JT; Conley PB
    Res Pract Thromb Haemost; 2020 Nov; 4(8):1282-1294. PubMed ID: 33313467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
    Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
    Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
    J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
    Dobesh PP; Fermann GJ; Christoph MJ; Koch B; Lesén E; Chen H; Lovelace B; Dettling T; Danese M; Ulloa J; Danese S; Coleman CI
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102192. PubMed ID: 37753225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.
    Pathan S
    Hosp Pharm; 2024 Aug; 59(4):394-406. PubMed ID: 38919755
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Thrombin Generation with 4-Factor Prothrombin Complex Concentrates in Neonatal Plasma After Cardiopulmonary Bypass.
    Franklin SW; Szlam F; Fernandez JD; Leong T; Tanaka KA; Guzzetta NA
    Anesth Analg; 2016 Apr; 122(4):935-42. PubMed ID: 26599794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
    Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
    Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.
    Chuck CC; Kim D; Kalagara R; Rex N; Madsen TE; Mahmoud L; Thompson BB; Jones RN; Furie KL; Reznik ME
    Neurology; 2021 Nov; 97(21):e2054-e2064. PubMed ID: 34556569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series.
    Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM
    Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding.
    Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW
    Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale.
    Shaw JR; Unachukwu U; Cyr J; Siegal DM; Castellucci LA; Dreden PV; Dowlatshahi D; Buyukdere H; Ramsay T; Carrier M
    TH Open; 2023 Jul; 7(3):e229-e240. PubMed ID: 37497426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.